Thaindian News

June 18, 2010 (Pen Men at Work): On Thursday, the Food and Drug Administration (FDA) of America endorsed the initial prostate cancer chemotherapy drug. This drug has been described as one that possesses the ability to prolong the survival of males, who are not responding effectively to other treatments.

The drug in question has been labeled Jevtana. It is manufactured by Sanofi-Aventis of France. The FDA has ratified Jevtana to treat prostate cancer that does not react constructively to hormone-deprivation treatments or to docetaxel. Docetaxel is the cancer medicine that has been utilized frequently to battle prostate tumors. Earlier this year, an investigation demonstrated that Jevtana lengthened survival for those patients by 10 weeks.

In the aforementioned investigation, the conclusion that was reached was that patients on Jevtana are expected to witness the decrease of their tumors more than the patients, who are being subjected to normal chemotherapy. Nonetheless, no patients in the investigation underwent an entire decrease or experienced the vanishing of all the signals of the malady.

Jevtana has received endorsement from the FDA to be utilized in amalgamation with the steroid, prednisone. Prednisone is regularly employed in the process of treatment of cancer. There is a wish among medicinal experts that Jevtana will have a constructively decisive impact on patients, who are not as ailing.

Jevtana is supplied by injection. The FDA has, however, articulated that Jevtana’s unconstructive offshoots consisted of diminished levels of infection-fighting white blood cells, anemia, dangerous levels of blood platelets, exhaustion, queasiness, constipation, feebleness and kidney breakdown.

The FDA’s authorization of Jevtana has appeared more than 3 months in advance as the FDA was listed to make an enunciation on the drug by the end of September. The FDA has also mentioned that prostate cancer is the second most prevalent cancer among men in America.